Tolerx's scientific advisory board to advance Type 1 diabetes research

CAMBRIDGE, Mass. A company that develops drugs for treating autoimmune diseases and cancer has created a scientific advisory board as part of its efforts to create treatments for Type 1 diabetes.

Tolerx said the four-member board would support the development of its lead drug candidate, otelixizumab, and guide future research and development in the Type 1 diabetes area.

“We at Tolerx are committed to developing a new therapeutic paradigm in Type 1 diabetes, and we have made great strides thus far with our ‘DEFEND’ program, including two ongoing phase-3 clinical trials of otelixizumab, our lead drug candidate for Type 1 diabetes,” Tolerx president and CEO Douglas Ringler said.